<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738893</url>
  </required_header>
  <id_info>
    <org_study_id>116850</org_study_id>
    <nct_id>NCT01738893</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of 300 mg Gabapentin</brief_title>
  <official_title>Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to confirm if two formulations of gabapentin (capsules) are
      bioequivalent.

      Test product was Darbetin® 300 mg (Laboratorios Dermatológicos Darier) and reference product
      Nerotin® 300 mg (Pfizer). One capsule was the single dosage.

      The study was prospective, open-label, randomized, crossover, single dose, with 02
      treatments, 02 sequences and 02 periods, under fasting conditions.

      The population was composed of 26 healthy volunteers, both genders, adults between 18-55
      years.

      The comparative bioavailability of the two formulations was evaluated based in statistical
      comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations
      in blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2011</start_date>
  <completion_date type="Actual">January 22, 2011</completion_date>
  <primary_completion_date type="Actual">January 22, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of drug gabapentin</measure>
    <time_frame>0.0, 0.50, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, and 24.0 postdosage</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of gabapentin</measure>
    <time_frame>0.0, 0.50, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, and 24.0 postdosage</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of test and cross-over to reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of reference and cross-over to test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300 mg</intervention_name>
    <description>Test product</description>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <other_name>Darbetin®</other_name>
    <other_name>Laboratorios Dermatologicos Darier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300 mg</intervention_name>
    <description>Reference product</description>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <other_name>Nerotin®</other_name>
    <other_name>Pfizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males 18-55 years. Healthy based on comprehensive medical history, lab tests, Chest x-ray,
        Electrocardiogram, negative tests for Hepatitis B and C, and HIV. Negative urine doping
        test. BMI 19-26.5 kg/m2. Lab test in normal range +/- 10%. Blood pressure 139-90/89-50,
        heart rate 100-55, respiratory rate 24-17, temperature 37.5-35 °C. Non-smoking at least for
        10 hrs before study. Written informed consent. Women must be not pregnant, nor
        breast-feeding.

        Exclusion Criteria:

        Hypersensitivity to study medication or other related drug. History of cardiovascular,
        renal, hepatic, metabolic, gastrointestinal, neurologic, endocrine, hematopoietic,
        psychiatric or organic condition.

        Requiring any drug interfering with minocycline pharmacokinetics. Exposed to inducers or
        inhibitors of hepatic enzymes. Intake of possible toxic drugs 30 days before study. Intake
        of any drug 14 days or 7 half-lives before study. Hospitalization or severe disease 60 days
        before study. Receiving investigational drug out of study center 30 days before study.
        Blood loss or blood donation =&gt;450 ml 60 days before study. Recent history of drug abuse
        including alcohol. Intake of xanthine containing products 10 hrs before study. Intake of
        grapefruit juice or hot-spice 10 hrs before study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/116850?search=study&amp;search_terms=116850#rs</url>
    <description>Results for study 116850 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mexico</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

